<code id='D7E3B4C194'></code><style id='D7E3B4C194'></style>
    • <acronym id='D7E3B4C194'></acronym>
      <center id='D7E3B4C194'><center id='D7E3B4C194'><tfoot id='D7E3B4C194'></tfoot></center><abbr id='D7E3B4C194'><dir id='D7E3B4C194'><tfoot id='D7E3B4C194'></tfoot><noframes id='D7E3B4C194'>

    • <optgroup id='D7E3B4C194'><strike id='D7E3B4C194'><sup id='D7E3B4C194'></sup></strike><code id='D7E3B4C194'></code></optgroup>
        1. <b id='D7E3B4C194'><label id='D7E3B4C194'><select id='D7E3B4C194'><dt id='D7E3B4C194'><span id='D7E3B4C194'></span></dt></select></label></b><u id='D7E3B4C194'></u>
          <i id='D7E3B4C194'><strike id='D7E3B4C194'><tt id='D7E3B4C194'><pre id='D7E3B4C194'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:91
          Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022
          Photo illustration: STAT; Photo: Adobe

          Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

          Lin alleges in a lawsuit that prominent oncologist Padmanee Sharma derailed the publication of papers based on Lin’s work, threatened to undermine her fledgling career, and made defamatory comments about her in retaliation for resisting making Sharma an author on a paper and saying the senior researcher had made no substantial contribution to it.

          advertisement

          “Having this and another paper taken — what would’ve been important papers for my career,” Lin told STAT in an interview. “I’m sure that my career in research has just fallen off a cliff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline
          Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

          DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Bernie Sanders gets little from pharma CEOs on drug prices

          Sen.BernieSanders(I-Vt.)raiseshishandataThursdayhearingonCapitolHillinWashingtontoexaminethecostofpr